CHDI
Alnylam, Medtronic, and CHDI Foundation Form Collaboration to Advance RNAi Therapeutics for the Treatment of Huntington’s Disease
Cambridge, Mass., Minneapolis, and New York City – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), Medtronic Inc. (NYSE:MDT), and CHDI Foundation, Inc., announced today that they have formed a collaboration to advance ALN-HTT, a novel drug-device ...Read More
The Public Library of Science, with support from CHDI Foundation Inc., has launched PLoS Currents: Huntington Disease
PLoS Currents is expanding September 2, 2010,PLoS (Public Library of Science, ...Read More
CHDI Foundation, Inc. and the National Institute of Neurological Disorders and Stroke (NINDS) launch joint program to support the validation of novel therapeutic targets for Huntington’s disease
New York City, NY - CHDI Foundation, Inc. (CHDI) and the National Institute of Neurological Disorders and Stroke (NINDS) have released a funding opportunity announcement (FOA) regarding an extramural program to preclinically validate therapeutic targ ...Read More
CHDI Foundation, Inc to carry out High Q Foundation’s research activities in Huntington’s disease
CHDI, Inc., recently renamed CHDI Foundation, Inc., and High Q Foundation, Inc. announced that CHDI has taken over primary responsibility for the types of Huntington’s disease research projects previously funded by High Q. CHDI will now b ...Read More